Drug Type CRISPR/Cas9 |
Synonyms Betaglobin gene therapy Allife Medical Science and Technology, Induced haematopoietic stem cells Allife Medical Science and Technology |
Target |
Action modulators |
Mechanism β-globin modulators(Hemoglobin beta chain modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Beta-Thalassemia | Phase 1 | - | 01 Jan 2019 |





